Rather than pursuing dual therapy, the clinical approach involves selecting the single agent most suited to your metabolic profile, weight management goals, and genetic predispositions
Whats more, almost 60% of participants in this group lost 20% or more of their body weight
A higher dose formulation of semaglutide (Wegovy, 2.4 mg) has been approved for weight management under NICE guidance (TA875)
selection should consider presence of cardiovascular disease, heart failure, or chronic kidney disease DPP-4 inhibitors (such as sitagliptin or linagliptin) oral agents with a different mechanism Insulin therapy particularly if glycaemic control is inadequate with oral agents Pioglitazone may be appropriate in selected patients without heart failure Sulfonylureas (such as gliclazide) though associated with hypoglycaemia and weight gain Your diabetes specialist or GP will conduct a comprehensive review of your treatment plan, considering factors such as HbA1c targets, cardiovascular risk profile, renal function, and personal preferences
It is suitable for all skin types, including sensitive and mature skin
